CD274 and cancer: Although the research focus has been on molecular factors (e.g., PD-L1 expression; MSI status; or tumor mutational burden), it is undeniable that patient-related factors (e.g., age, sex, and performance status) can modulate the impact of ICIs on cancer patients in general and GI cancer patients in particular.